Oxidative Stress—the Key Mechanism of Diabetic Peripheral Neuropathy
Abstract
In China, there are more than one hundred million people with diabetes, among which 60% have diabetic peripheral neuropathy (DPN). However, because of the unclear mechanism there is no effective drug for DPN. In this review, we present the current oxidative stress hypothesis and the relationship between the classical and accepted DPN mechanism pathways and oxidative stress. Furthermore, the two signal pathways are important for oxidative stress. Recent studies have focused on the intracellular oxidative stress, especially from mitochondria. As the foremost energy metabolic organelle mitochondria is affected in many aspects after hyperglycemia. Better understanding of the relationship between DPN and oxidative stress may provide insights into new drug therapies.
[N A J Med Sci. 2013;6(2):87-90. DOI: 10.7156/najms.2013.0602087]
Keywords
References
Bin Lua, Zhihong Yang, MeiWang, et al. High prevalence of diabetic neuropathy in population-based patients diagnosed with type 2 diabetes in the Shanghai downtown. Diabetes research and clinical practice. 2010;88(3):289–294.
Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care. 2010;33(10):2285-2293.
Attinger CE, Brown BJ. Amputation and ambulation in diabetic patients: function is the goal. Diabetes Metab Res Rev. 2012;28(Suppl 1):93-96.
Smith SC, Lamping DL, Maclaine GD. Measuring health-related quality of life in diabetic peripheral neuropathy: a systematic review. Diabetes Res Clin Pract. 2012;96(3):261-270.
Hinder LM, Vincent AM, Burant CF, Pennathur S, Feldman EL. Bioenergetics in diabetic neuropathy: what we need to know. J Peripher Nerv Syst. 2012;17(Suppl 2):10-14.
Hinder LM, Vivekanandan-Giri A, McLean LL, Pennathur S, Feldman EL. Decreased glycolytic and tricarboxylic acid cycle intermediates coincide with peripheral nervous system oxidative stress in a murine model of type 2 diabetes. J Endocrinol. 2013;216(1):1-11.
Brownlee M. The pathobiology of diabetic complications. Diabetes. 2005;54(6):1615-1625.
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813-820.
Antonio Ceriello. New Insights on Oxidative Stress and Diabetic Complications May Lead to a “Causal” antioxidant Therapy. Diabetes Care. 2003;26(5):1589–1596.
Antonio Ceriello, Enrico Motz. Is Oxidative Stress the Pathogenic Mechanism Underlying Insulin Resistance, Diabetes, and Cardiovascular Disease? Arterioscler Thromb Vasc Biol. 2004;24(5):816-823.
Wada R, Yagihashi S. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann N Y Acad Sci. 2005;1043:598-604.
Srivastava SK, Ramana KV, Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev. 2005;26(3):380–392.
Hotta N, Kawamori R, Fukuda M, Shigeta Y; Aldose Reductase Inhibitor-Diabetes Complications Trial Study Group. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy. Diabet Med. 2012;29(12):1529-1533.
King RH. The role of glycation in the pathogenesis of diabetic polyneuropathy. Mol Pathol. 2001;54(6):400–408.
Vincent AM, Perrone L, Sullivan KA, et al. Receptor for Advanced Glycation End Products Activation Injures Primary Sensory Neurons via Oxidative Stress. Endocrinology. 2007;148(2):548-558.
Jack M, Wright D. Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy. Transl Res. 2012;159(5):355-365.
Mizukami H, Ogasawara S, Yamagishi S, Takahashi K, Yagihashi S. Methylcobalamin effects on diabetic neuropathy and nerve protein kinase C in rats. Eur J Clin Invest. 2011;41(4):442-450.
Gopalakrishna R, Jaken S. Protein kinase C signaling and oxidative stress. Free Radic Biol Med. 2000;28(9):1349–1361.
Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res. 2010;106(8):1319-1331.
Figueroa-Romero C, Sadidi M, Feldman EL.Mechanisms of disease: the oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord. 2008;9(4):301-314.
Luong KV, Nguyen LT. The impact of thiamine treatment in the diabetes mellitus. J Clin Med Res. 2012;4(3):153-160.
Várkonyi T, Putz Z, Keresztes K, et al. Current options and perspectives in the treatment of diabetic neuropathy. Curr Pharm Des. 2012. [Epub ahead of print]
Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: the oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord. 2008;9(4):301-314.
Kasznicki J, Kosmalski M, Sliwinska A, et al. Evaluation of oxidative stress markers in pathogenesis of diabetic neuropathy. Mol Biol Rep. 2012;39(9):8669-8678.
El Boghdady NA, Badr GA. Evaluation of oxidative stress markers and vascular risk factors in patients with diabetic peripheral neuropathy. Cell Biochem Funct. 2012;30(4):328-334.
Obrosova IG, Li F, Abatan OI, et al. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes. 2004;53(3):711–720.
Du X, Matsumura T, Edelstein D, et al. Inhibition of GAPDH activity by poly (ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest. 2003;112(7) :1049 –1057.
Terashima T, Kojima H, Chan L. Bone marrow expression of poly(ADP-ribose) polymerase underlies diabetic neuropathy via hematopoietic-neuronal cell fusion. FASEB J. 2012;26(1):295-308.
Cavaletti G, Miloso M, Nicolini G, et al. Emerging role of mitogen-activated protein kinases in peripheral neuropathies. Peripher Nerv Syst. 2007;12(3):175-194.
Tomlinson DR, Gardiner NJ. Diabetic neuropathies: components of etiology. Peripher Nerv Syst. 2008;13(2):112-121.
Purves T, Middlemas A, Agthong S, et al. A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB. 2001;15(13):2508-2514.
Price SA, Agthong S, Middlemas AB, Tomlinson DR. Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: interactions with aldose reductase. Diabetes. 2004;53(7):1851-1856.
Stavniichuk R, Shevalye H, Hirooka H, Nadler JL, Obrosova IG. Interplay of sorbitol pathway of glucose metabolism, 12/15-lipoxygenase, and mitogen-activated protein kinases in the pathogenesis of diabetic peripheral neuropathy. Biochem Pharmacol. 2012;83(7):932-940.
Akude E, Elena Zherebitskaya E, S K Chowdhury SK, , Smith DR, Dobrowsky RT, Fernyhough P. Diminished Superoxide Generation Is Associated With Respiratory Chain Dysfunction and Changes in the Mitochondrial Proteome of Sensory Neurons From Diabetic Rats. Diabetes. 2011;60(1):288-297.
Chowdhury SK, Zherebitskaya E, Smith DR, et al. Mitochondrial respiratory chain dysfunction in dorsal root ganglia of streptozotocin-induced diabetic rats and its correction by insulin treatment. Diabetes. 2010;59(4):1082–1091.
Akude E, Zherebitskaya E, Roy CSK, Girling K, Fernyhough P. 4-Hydroxy-2-nonenal induces mitochondrial dysfunction and aberrant axonal outgrowth in adult sensory neurons that mimics features of diabetic neuropathy. Neurotox Res. 2010;17(1):28-38.
Chowdhury SK, Zherebitskaya E, Smith DR, et al. Mitochondrial respiratory chain dysfunction in dorsal root ganglia of streptozotocin-induced diabetic rats and its correction by insulin treatment. Diabetes. 2010;59(4):1082–1091.
Edwards JL, Quattrini A, Lentz SI, et al. Diabetes regulates mitochondrial biogenesis and fission in mouse neurons. Diabetologia. 2010;53(1):160-169.
Junguk Hur, Kelli A Sullivan, Eva L Feldman. Literature-based discovery of diabetes- and ROS-related targets. BMC Med Genomics. 2010;3:49.
Vincent AM, Russell JW, Sullivan KA, et al. SOD2 protects neurons from injury in cell culture and animal models of diabetic neuropathy. Exp Neurol. 2007;208(2):216-227.
Bugger H, Boudina S, Hu XX, et al. Type 1 diabetic akita mouse hearts are insulin sensitive but manifest structurally abnormal mitochondria that remain coupled despite increased uncoupling protein 3. Diabetes. 2008;57(11):2924-2932.
Echtay KS, Roussel D, St-Pierre J, et al. Superoxide activates mitochondrial uncoupling proteins. Nature. 2002(6867);415:96 –99.
Han T, Bai J, Liu W, Hu Y. A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol. 2012;167(4):465-471.
Hernández-Ojeda J, Cardona-Muñoz EG, Román-Pintos LM, et al. The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study. J Diabetes Complications. 2012;26(4):352-358.
Valensi P, Le Devehat C, Richard JL, et al. A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005;19(5):247-253.
Shevalye H, Watcho P, Stavniichuk R, et al. Metanx alleviates multiple manifestations of peripheral neuropathy and increases intraepidermal nerve fiber density in Zucker diabetic fatty rats. Diabetes. 2012;61(8):2126-2133.
Ziegler D. Painful diabetic neuropathy: advantage of novel drugs over old drugs. Diabetes Care. 2009;32(Suppl 2):S414-S419.
Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011;7(10):573-583.
Refbacks
- There are currently no refbacks.